Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

European Medicines Agency 

EMA orders medicine name changes for first time to reduce errors

For the first time, drug companies across Europe have been told to change the names of medicines containing liposomal in their drug delivery systems following reports of medication errors that have led to patient deaths.

In the first decision of its kind, published on 31 July 2019, the European Medicines Agency (EMA) has told companies to make a clearer distinction between liposomal and non-liposomal formulations of the same active substance to avoid future medication errors.

Companies have until the end of September 2019 to make the changes to the drug names.

The two formulations may have different biodistribution and release properties, which means medication errors can pose serious risks to patient safety, it warned.

It said that the two formulations are at particular risk of being mixed up when electronic prescribing and dispensing tools are used.

The EMA wants companies to make a clear distinction between ‘liposomal’ or ‘pegylated liposomal’ in the summary of product characteristics and product information.

The recommendations come jointly from the EMA’s Committee for Medicinal Products for Human Use and its Coordination Group for Mutual Recognition and Decentralised Procedures — Human.

The EMA confirmed to The Pharmaceutical Journal that this was the first time that it had requested marketing authorisation holders to update their product name to avoid medication errors.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206891

Readers' comments (1)

  • I was 'on the register' from 1968 to about 2007, and it is only now that I get to know that, if somebody needed to know if she would have trouble with PPD hair-dyes, she would have to go to her doctor, get a (presumably private) prescription, and then buy the test-kit. I might be off the register, but I'm still learning. We must be all so relieved to know that we can sell it now. Wonder what sort of shelf-life it has.

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.